Application

Plato Data Intelligence Leverages Vectara to Power its Data-As-A-Service / DaaS Platform

From development to launch, Vectara’s GenAI technology and team help innovators get to market faster. The announced partnership breaks new ground towards deploying a next generation of GenAI tools with Vertical focus. Vectara, the Trusted Generative AI Product Platform, and Plato Data Intelligence, creators of PlatoAi, have entered into a commercial agreement to unlock the power of Vectara via Plato AI’s Generative Intelligence platform. With an emphasis on secure, trustworthy, and transparent GenAI for enterprises, Vectara was the clear choice for developers who want a trusted provider to count on

United Nations IGF Dynamic Coalition Pilots a Decentralized Autonomous Organization (DAO)

New York, NY – December 20, 2023 — The United Nations Internet Governance Forum (IGF) Dynamic Coalition on Blockchain Assurance & Standardization announces the initiation of a groundbreaking project aimed at establishing a Distributed Autonomous Organization (DAO). The pilot project is a collaborative effort showcasing how public sector organizations can leverage blockchain technology and DAO principles to foster transparent, rules-based, and high-integrity governance structures. UN - IGF Dynamic Coalitions are multistakeholder groups operating within the framework of the UN Internet Governance Forum, addressing specific issues related to internet governance. These

JCB, IDEMIA and Soft Space launch “JCBDC” Phase 2 pilot to trial CBDC offline P2P payments

Tokyo, Paris, Kuala Lumpur, Dec 13, 2023 - (JCN Newswire) - Japan's only international payment brand JCB Co., Ltd. ("JCB") has launched the “JCBDC” (JCB Digital Currency) Phase 2 pilot project with IDEMIA, a global leader in identity technologies, and the world’s leading fintech company Soft Space Sdn Bhd. ("Soft Space"). In Phase 1 of the JCBDC project, JCB, IDEMIA, and Soft Space developed a CBDC (Central Bank Digital Currency) payment solution, enabling merchants to accept CBDC without the need to modify their POS (point of sale) terminals and payment

NKGEN Biotech Received FDA Approval for Clinical Trials of SKN01 NK Cell Therapy in Alzheimer’s Disease Treatment.

Summary: Progress in Neurodegenerative Research:  NKGen’s Phase 1/2a Clinical Trial for SNK01 on Track for End-of-Year Initiation SANTA ANA, Calif., Oct. 24, 2023 (Plato / Amplifi) -- Today, NKGen Biotech Inc. (Nasdaq: NKGN), a trailblazer in the field of autologous, allogeneic, and CAR-NK natural killer cell therapeutics, proudly announced the progression of its SNK01 program targeting Alzheimer’s Disease (AD), backed by the green light from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application. NKGen is gearing up to initiate its Phase 1/2a clinical trial

Paribus on the Rise

The past few weeks have seen a whirlwind of activity for the team, bridging over to Cardano and raising awareness of Paribus. The upcoming weeks and months will be equally exciting as we are poised to deliver more elements from our roadmap. As more of the circulating PBX supply transitions to Cardano, we’ve been making strides toward getting the token listed on two more decentralized exchanges (DEXs). We’ll be able to announce each one as they launch, so stay tuned to our Discord, Twitter, and Telegram channels for the latest

Coya Therapeutics Reports Additional Biomarker and Imaging Data Showing Decrease in Neuroinflammation with COYA 301 in Alzheimer’s Disease.

Highlights Coya reports new data illustrating that administration of COYA 301 (low dose Interleukin-2 (IL-2)) in an open- label study in 8 patients with mild to moderate AD (COYA 301 Trial) resulted in a statistically significant reduction in the expression of three well characterized proinflammatory cytokines -- Tumor Necrosis Factor alpha (TNF-α), Interleukin 6 (IL-6), and Interleukin 1- Beta (IL-1β) -- which correlated with lack of cognitive decline of the patients over the course of the study. TNF-α is one of the main inflammatory cytokines involved in initiating and propagating

DCM DAY: WEB3 AND THE FUTURE OF MEDIA

Geneva, Switzerland – DCM Swiss, a Digital Content Marketplace, is excited to announce a special event taking place during the Open Geneva Innovation Festival on March 17th at 2:30 PM CET. DCM DAY will focus on the exciting topic of Web3 and the Future of Media, exploring the latest developments and innovations in this rapidly-evolving field. The event will be held at Fédération des Entreprises Romandes Genève, 98 Rue de Saint-Jean, Genève, GE, 1201. DCM DAY promises to be a must-attend event for anyone interested in the future of media,

The Most Popular Photo Editing Software In 2023

Any photographer wonders what is the best photo enhancer, and never all photographers in the world will agree on the answer. The choice depends on different directions, styles, and genres. Maybe you are a photographer who has just begun to learn the craft, and you don't fully understand what you need, so you are looking for everything in one application. Or maybe you are an active user of social networks, looking for an app available to you, given the level of mastery of the photo post-processing process, or rather the